Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.UMRX · Entity 3793 | Chief Financial Officer | February 11, 2020 | February 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date February 11, 2020 · Filed February 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2030-02-11 | Direct | 160,400 |
Reported balance
After 2020-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-11 · Grant · Acquired 160,400 · Balance 160,400 F1: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2020 Filed Feb 13, 2020 21:55 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option · Derivative | 160,400 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-009293 · doc4.xml · derivative · entry 1 Osborne Matthew Scott · CIK 0001780543 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,400 Underlying: Common Stock · 160,400 shares Expires 2030-02-11 F1 · derivative.exercise_date: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 20:51 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001209191-19-038965 · doc4.xml · derivative · entry 1 Osborne Matthew Scott · CIK 0001780543 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This stock option shall vest as follows: 25% on the first anniversary of the date of grant then in equal monthly installments over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.